<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616029</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-292-1824</org_study_id>
    <secondary_id>2015-002710-74</secondary_id>
    <nct_id>NCT02616029</nct_id>
  </id_info>
  <brief_title>Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I</brief_title>
  <official_title>A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir
      alafenamide (E/C/F/TAF) fixed dose combination (FDC) after switching from a stable regimen
      consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine
      (ABC/3TC) plus a third antiretroviral agent in participants harboring the archived
      nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or
      M184I in HIV-1 reverse transcriptase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Week 12 as defined by pure virologic response (PVR)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with emergence of new mutations in HIV-1 reverse transcriptase and integrase</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>This outcome measure will be assessed with any post Day 1 sample with HIV-1 RNA ≥ 50 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Weeks 24 and 48 using PVR</measure>
    <time_frame>Weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Weeks 12, 24 and 48 using the FDA snapshot analysis</measure>
    <time_frame>Weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with CD4+ cell count change from Day 1 at Weeks 12, 24 and 48</measure>
    <time_frame>Day 1, Weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>E/C/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will switch from their current regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF FDC and will receive treatment for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF</intervention_name>
    <description>E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily</description>
    <arm_group_label>E/C/F/TAF</arm_group_label>
    <other_name>Genvoya®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documented historical genotype report showing M184V and/or M184I (mixtures are
             acceptable) in reverse transcriptase. Individuals must not have any primary integrase
             strand transfer inhibitor (INSTI) or primary protease inhibitor (PI) resistance
             mutations present on historical genotype; non-nucleoside reverse transcriptase
             inhibitor (NNRTI) mutations are allowed.

          -  Proviral DNA test must not have additional exclusion resistance mutations against PIs,
             NRTIs and INSTIs

               -  Part 1 (first 50 individuals): Historical genotype report must show M184V and/or
                  M184I in reverse transcriptase WITHOUT any other NRTI resistance mutation
                  (including thymidine analogue-associated mutations (TAMs) [TAMs are: M41L, D67N,
                  K70R, L210W, T215Y/F, and K219Q/E/N/R], K65R, T69 insertion and Q151M mutation
                  complex [A62V, V75I, F77L, F116Y, Q151M]

               -  Part 2 (after the interim efficacy review - 50 individuals): Historical genotype
                  report must show M184V and/or M184I in reverse transcriptase WITH or WITHOUT one
                  or two thymidine analogue-associated mutations (TAMs) [TAMs are: M41L, D67N,
                  K70R, L210W, T215Y/F, and K219Q/E/N/R]. Evidence of K65R, K70E, T69 insertion
                  and/or Q151M mutation complex [A62V, V75I, F77L, F116Y, Q151M] will not be
                  eligible

          -  Currently receiving an antiretroviral regimen consisting of FTC/TDF or ABC/3TC in
             combination with one third antiretroviral agent for ≥ 6 consecutive months preceding
             the screening visit

          -  Documented plasma HIV-1 RNA levels &lt; 50 copies/mL for ≥ 6 months preceding the
             screening visit

          -  Plasma HIV-1 RNA levels &lt; 50 copies/mL at screening visit

          -  Estimated glomerular filtration rate (GFR) ≥ 30 mL/min according to the
             Cockcroft-Gault formula for creatinine clearance

          -  A female individual is eligible to enter the study if it is confirmed that she is:

               -  not pregnant

               -  of non-childbearing potential

               -  stopped menstruating for ≥ 12 months

               -  of childbearing potential and agrees to utilize the protocol specified method of
                  contraception or be non-heterosexually active or practice sexual abstinence from
                  screening throughout the duration of study treatment and for 30 days following
                  discontinuation of study drugs

          -  Male individuals must agree to use the protocol specified method(s) of contraception
             during heterosexual intercourse or be non-heterosexually active, or practice sexual
             abstinence from screening throughout the study period and for 30 days following the
             last study drug dose

               -  Male individuals must agree to refrain from sperm donation from first dose until
                  at least 30 days after the last study drug dose

        Key Exclusion Criteria:

          -  Individuals will have no evidence of previous virologic failure on a PI/r or
             INSTI-based regimen (with or without resistance to either class of ARV). Individuals
             may have evidence of prior virologic failure on only an NNRTI plus 2 NRTI-based
             regimen

          -  Individuals on a current PI/r-based regimen will have no evidence of previous use of
             any approved or experimental integrase strand transfer inhibitor (INSTI) (for any
             length of time)

          -  Hepatitis C infection that would require therapy during the study

          -  Hepatitis B surface antigen (HBsAg) positive

          -  Individuals with clinical evidence of decompensated cirrhosis (e.g., ascites,
             encephalopathy, variceal bleeding, etc.)

          -  Have an implanted defibrillator or pacemaker

          -  A history of malignancy within the past 5 years (prior to screening) or ongoing
             malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
             resected, non invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are
             eligible, but must not have received any systemic therapy for KS within 30 days of Day
             1 and must not be anticipated to require systemic therapy during the study

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to Day 1

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GS-US-292-1824@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Men's Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gary Richmond, MD, PA, Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology &amp; Research Center, LLC</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Southwest CARE Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, MD</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Marguerite - Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice-l Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Orleans la Source</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu</name>
      <address>
        <city>Paris Cedex 14</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker les Enfants Malades</name>
      <address>
        <city>Paris Cedex 15</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque - Service Médecine Interne</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Tours Service de Médecine Internes et Maladies Infectieuses</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Infektiologikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICH Study Center- Dedicated Research</name>
      <address>
        <city>Hamburg</city>
        <zip>22083</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Malattie Infettive e Tropicali dell'Università di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS San Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Roma Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Malattie Infettive e Tropicali</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona - Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre - Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario De Málaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario De Vigo - Hospital Alvaro Cunqueiro Servicio de Medicina Interna</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

